Prices Plunge As Xarelto Generics Arrive In India
Partner Zydus Cadila Debuts Another Rivaroxaban Brand
Executive Summary
More than half a dozen generic rivaroxaban brands are now available in India, putting the heat on Bayer’s blockbuster anticoagulant Xarelto in the price-sensitive market. Many rival generics are priced over 50% lower than the innovator product.
You may also be interested in...
Troubled Bayer Boosted By Big Two Pharma Earners
While the legal woes over the seeds giant Monsanto continue, the German group's pharmaceuticals business posts unspectacular third quarter results.
Accord Gets First EU-Wide Nod For Xarelto Rival
Accord Healthcare has garnered the first positive opinion recommending granting a pan-European marketing authorization for a generic version of rivaroxaban from the EMA’s CHMP. However, originator Bayer claims that no generic competition will be possible for another three years.
Indian Court Rebuffs Bayer In Bolar Exemption Case
The Delhi High Court has rejected Bayer’s contention around certain key aspects of India’s Bolar provision – the experimental use or early working exception – and held that “sale” both within the country and abroad is permitted under these norms, subject to certain conditions.